A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain metastases (SPIRAL-BRAIN study) [0.03%]
雷莫卢单抗联合厄洛替尼治疗伴有脑转移的表皮生长因子受体突变阳性且未经治疗的非小细胞肺癌患者Ⅱ期单组、前瞻性和开放性多中心研究（SPIRAL-BRAIN研究）
Ryo Sawada,Naoya Nishioka,Young Hak Kim et al.
Ryo Sawada et al.
Background: The combination of erlotinib, a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and ramucirumab, an anti-vascular endothelial growth factor receptor (VEGFR) antibody, is...
Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy [0.03%]
基线和免疫治疗早期外周血中性粒细胞-淋巴细胞比值、C反应蛋白和乳酸脱氢酶对非小细胞肺癌患者预后价值的研究
MinDong Sung,Won Seok Jang,Hae Reong Kim et al.
MinDong Sung et al.
Background: Not all non-small cell lung cancer (NSCLC) patients will benefit from immune checkpoint therapy and use of these medications carry serious autoimmune adverse effects. Therefore, biomarkers are needed to better...
Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? [0.03%]
术后辅助使用奥希替尼治疗表皮生长因子受变异非小细胞肺癌：改变游戏规则？
Shruti R Patel,Joel W Neal
Shruti R Patel
First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic [0.03%]
表皮生长因子受体突变的晚期非小细胞肺癌患者一线使用奥希替尼治疗：在新冠疫情期间疗效及安全性分析
Suganija Lakkunarajah,Pauline T Truong,Jeffrey N Bone et al.
Suganija Lakkunarajah et al.
Background: The FLAURA trial demonstrated improved overall survival (OS) with first-line osimertinib for patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). We studie...
Targeting gene fusions in non-small cell lung cancer-a ceaseless success story? [0.03%]
非小细胞肺癌中的基因融合靶向治疗——不断成功的故事？
Per Hydbring
Per Hydbring
Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better? [0.03%]
可切除非小细胞肺癌的新辅助免疫化疗：周期越多越好吗？
Ezgi B Ulas,Idris Bahce
Ezgi B Ulas
Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation? [0.03%]
敬仰ADAURA：我们能否治愈EGFR突变型肺癌？
Barbara Melosky
Barbara Melosky
Learning curve for uniportal thoracoscopic pulmonary segmentectomy: how many procedures are required to acquire expertise? [0.03%]
单孔胸腔镜肺段切除术的学习曲线：掌握该技术需要多少例手术经验？
Natsumi Matsuura,Hitoshi Igai,Fumi Ohsawa et al.
Natsumi Matsuura et al.
Background: Minimally invasive surgeries are increasingly being performed. However, few studies have evaluated the learning curve for uniportal thoracoscopic segmentectomies. Therefore, we investigated the learning curve ...
Identification of lysosomal genes associated with prognosis in lung adenocarcinoma [0.03%]
鉴定与肺腺癌预后相关的溶酶体基因
Houqiang Li,Xinyu Sha,Wenmiao Wang et al.
Houqiang Li et al.
Background: Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer, representing 40% of all cases of this tumor. Despite immense improvements in understanding the molecular basis, diagnosis, and treatment of...
Diagnostic accuracy and safety of electromagnetic navigation transthoracic needle biopsy under moderate sedation for the diagnosis of peripheral pulmonary lesions [0.03%]
中度镇静下电磁导航经皮肺穿刺活检诊断周围型肺部病变的准确性及安全性分析
SoJeong Kim,NaYoung Kim,SooJie Chung et al.
SoJeong Kim et al.
Background: Novel approaches using virtual computed tomography (CT) guidance, namely electromagnetic navigation transthoracic needle biopsy (EMN-TTNB), enable physicians to perform percutaneous lung biopsies. However, the...